{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:23:23Z","timestamp":1793363003897,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.kint.2026.06.033","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:22:05Z","timestamp":1784820125000},"page":"1262-1270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation"],"prefix":"10.1016","volume":"110","author":[{"given":"Thomas","family":"Drasch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9227-8017","authenticated-orcid":false,"given":"Aylin","family":"Akifova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Halleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-5942","authenticated-orcid":false,"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rohlfing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Grahammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kowald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Baatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-4914","authenticated-orcid":false,"given":"Stephan","family":"Kemmner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Seibt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareen","family":"Pigorsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bornemann-Kolatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Banas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2123-0310","authenticated-orcid":false,"given":"Daniel","family":"Zecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.06.033_bib1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1681\/ASN.2020081215","article-title":"Exploring the complexity of death-censored kidney allograft failure","volume":"32","author":"Mayrdorfer","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.kint.2026.06.033_bib2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00007890-200009270-00006","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2026.06.033_bib3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.TP.0000060252.57111.AC","article-title":"Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection","volume":"75","author":"Rocha","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2026.06.033_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.06.033_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2026.06.033_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.06.033_bib7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib9","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib10","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.033_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.kint.2021.11.029","article-title":"Allorecognition and the spectrum of kidney transplant rejection","volume":"101","author":"Callemeyn","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.033_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJMoa2408835","article-title":"Microvascular inflammation of kidney allografts and clinical outcomes","volume":"392","author":"Sablik","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.033_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14337","article-title":"Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection - the long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib15","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for antibody-mediated rejection: is it time to target the real culprit?","volume":"23","author":"de Nattes","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2026.06.033_bib17","article-title":"Case report: daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.06.033_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.kint.2026.06.033_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001685","article-title":"Targeting CD38 in subclinical antibody-mediated rejection in HLA-incompatible kidney transplantation: a case report","volume":"10","author":"Viklicky","year":"2024","journal-title":"Transplantation Direct"},{"key":"10.1016\/j.kint.2026.06.033_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.033_bib21","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41591-025-03653-3","article-title":"Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies","volume":"31","author":"Diebold","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.06.033_bib22","article-title":"TRANSCEND: a phase 3 trial of the anti-CD38 antibody felzartamab in kidney transplant recipients with late antibody-mediated rejection","volume":"25","author":"Bohmig","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001794","article-title":"Association of blood donor-derived cell-free DNA levels with Banff scores and histopathological lesions in kidney allograft biopsies: results from an observational study","volume":"11","author":"Akifova","year":"2025","journal-title":"Transplantation Direct"},{"key":"10.1016\/j.kint.2026.06.033_bib24","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/ajt.15416","article-title":"Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study","volume":"19","author":"Oellerich","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib25","series-title":"R A Language and Environment for Statistical Computing","year":"2025"},{"key":"10.1016\/j.kint.2026.06.033_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v064.i09","article-title":"nparcomp: an R software package for nonparametric multiple comparisons and simultaneous confidence intervals","volume":"64","author":"Konietschke","year":"2015","journal-title":"J Stat Soft"},{"key":"10.1016\/j.kint.2026.06.033_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65153-9","article-title":"Continuous indices to assess the phenotypic spectrum of kidney transplant rejection","volume":"16","author":"Vaulet","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.06.033_bib28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ajt.2026.01.018","article-title":"The Banff 2024 Kidney Meeting Report: rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning","volume":"26","author":"Naesens","year":"2026","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/tan.15458","article-title":"Daratumumab treatment in six highly sensitised solid organ transplant recipients: a case series and literature review","volume":"103","author":"Lemal","year":"2024","journal-title":"HLA"},{"key":"10.1016\/j.kint.2026.06.033_bib30","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.06.033_bib31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/ndt\/gfae282","article-title":"Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial","volume":"40","author":"Akifova","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib32","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41591-024-03087-3","article-title":"Cell-free DNA for the detection of kidney allograft rejection","volume":"30","author":"Aubert","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.06.033_bib33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajt.2024.08.004","article-title":"Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates","volume":"25","author":"Torija","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.06.033_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.06.033_bib35","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/TP.0000000000005228","article-title":"Functional natural killer-cell genetics and microvascular inflammation after kidney transplantation: an observational cohort study","volume":"109","author":"Diebold","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2026.06.033_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/tan.70560","article-title":"Acute rejection with DSA-negative severe microvascular inflammation in a kidney transplant recipient with an isolated DPB1\u221704-mismatch successfully stabilised with daratumumab","volume":"107","author":"Kn\u00f6dl","year":"2026","journal-title":"HLA"},{"key":"10.1016\/j.kint.2026.06.033_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13213","article-title":"Donor-derived cell-free DNA as a companion biomarker for AMR treatment with daratumumab: case series","volume":"37","author":"Osmanodja","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2026.06.033_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13239","article-title":"Perspective for donor-derived cell-free DNA in antibody-mediated rejection after kidney transplantation: defining context of use and clinical implications","volume":"37","author":"Akifova","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2026.06.033_bib39","first-page":"3148","article-title":"Infectious complications of daratumumab-containing therapy for multiple myeloma","volume":"130","author":"Johnsrud","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.06.033_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2026.06.033_bib41","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302214","article-title":"B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses","volume":"6","author":"Verhoeven","year":"2023","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.kint.2026.06.033_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2026.06.033_bib43","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ndt\/gfaf097","article-title":"Antibody-mediated rejection-treatment standard","volume":"40","author":"B\u00f6hmig","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:32:56Z","timestamp":1792488776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826006046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0085253826006046"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.033","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.07.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}